Journal of Dermatological Treatment (Apr 2022)

Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review

  • Ilse Andrea Moreno-Arquieta,
  • Jesus Alberto Cardenas-de la Garza,
  • Jorge Antonio Esquivel-Valerio,
  • Janett Riega-Torres,
  • Adrian Cuellar-Barboza,
  • Maira Elizabeth Herz-Ruelas,
  • Jorge Ocampo-Candiani,
  • Dionicio Angel Galarza-Delgado

DOI
https://doi.org/10.1080/09546634.2021.1890682
Journal volume & issue
Vol. 33, no. 3
pp. 1765 – 1768

Abstract

Read online

Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords ‘eosinophilic fasciitis’, ‘Shulman syndrome’, ‘mycophenolic acid’, or ‘mofetil mycophenolate’, and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects.

Keywords